| pubmed-article:18762671 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:18762671 | lifeskim:mentions | umls-concept:C0155626 | lld:lifeskim |
| pubmed-article:18762671 | lifeskim:mentions | umls-concept:C0151744 | lld:lifeskim |
| pubmed-article:18762671 | lifeskim:mentions | umls-concept:C1522318 | lld:lifeskim |
| pubmed-article:18762671 | lifeskim:mentions | umls-concept:C1948041 | lld:lifeskim |
| pubmed-article:18762671 | lifeskim:mentions | umls-concept:C0288672 | lld:lifeskim |
| pubmed-article:18762671 | lifeskim:mentions | umls-concept:C0205360 | lld:lifeskim |
| pubmed-article:18762671 | lifeskim:mentions | umls-concept:C0021953 | lld:lifeskim |
| pubmed-article:18762671 | lifeskim:mentions | umls-concept:C0814225 | lld:lifeskim |
| pubmed-article:18762671 | pubmed:issue | 9 | lld:pubmed |
| pubmed-article:18762671 | pubmed:dateCreated | 2008-9-2 | lld:pubmed |
| pubmed-article:18762671 | pubmed:abstractText | At 30 days, it is recognized that 12-hour periprocedural abciximab infusion protects against reinfarction and the need for revascularization in percutaneous coronary intervention (PCI) in acute myocardial infarction (MI). However, it is controversial whether the benefit to patients continues or fades away subsequently. We investigate whether abciximab provides a persistent advantage in terms of life-years gained in large trials of abciximab in PCI. | lld:pubmed |
| pubmed-article:18762671 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18762671 | pubmed:language | eng | lld:pubmed |
| pubmed-article:18762671 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18762671 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:18762671 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18762671 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18762671 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18762671 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18762671 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:18762671 | pubmed:month | Sep | lld:pubmed |
| pubmed-article:18762671 | pubmed:issn | 1557-2501 | lld:pubmed |
| pubmed-article:18762671 | pubmed:author | pubmed-author:FrancisDarrel... | lld:pubmed |
| pubmed-article:18762671 | pubmed:author | pubmed-author:MayetJamilJ | lld:pubmed |
| pubmed-article:18762671 | pubmed:author | pubmed-author:FoaleRodney... | lld:pubmed |
| pubmed-article:18762671 | pubmed:author | pubmed-author:FerencziEmily... | lld:pubmed |
| pubmed-article:18762671 | pubmed:author | pubmed-author:MalikIqbal... | lld:pubmed |
| pubmed-article:18762671 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:18762671 | pubmed:volume | 20 | lld:pubmed |
| pubmed-article:18762671 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:18762671 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:18762671 | pubmed:pagination | 437-41 | lld:pubmed |
| pubmed-article:18762671 | pubmed:dateRevised | 2010-11-18 | lld:pubmed |
| pubmed-article:18762671 | pubmed:meshHeading | pubmed-meshheading:18762671... | lld:pubmed |
| pubmed-article:18762671 | pubmed:meshHeading | pubmed-meshheading:18762671... | lld:pubmed |
| pubmed-article:18762671 | pubmed:meshHeading | pubmed-meshheading:18762671... | lld:pubmed |
| pubmed-article:18762671 | pubmed:meshHeading | pubmed-meshheading:18762671... | lld:pubmed |
| pubmed-article:18762671 | pubmed:meshHeading | pubmed-meshheading:18762671... | lld:pubmed |
| pubmed-article:18762671 | pubmed:meshHeading | pubmed-meshheading:18762671... | lld:pubmed |
| pubmed-article:18762671 | pubmed:meshHeading | pubmed-meshheading:18762671... | lld:pubmed |
| pubmed-article:18762671 | pubmed:meshHeading | pubmed-meshheading:18762671... | lld:pubmed |
| pubmed-article:18762671 | pubmed:meshHeading | pubmed-meshheading:18762671... | lld:pubmed |
| pubmed-article:18762671 | pubmed:meshHeading | pubmed-meshheading:18762671... | lld:pubmed |
| pubmed-article:18762671 | pubmed:meshHeading | pubmed-meshheading:18762671... | lld:pubmed |
| pubmed-article:18762671 | pubmed:meshHeading | pubmed-meshheading:18762671... | lld:pubmed |
| pubmed-article:18762671 | pubmed:meshHeading | pubmed-meshheading:18762671... | lld:pubmed |
| pubmed-article:18762671 | pubmed:meshHeading | pubmed-meshheading:18762671... | lld:pubmed |
| pubmed-article:18762671 | pubmed:meshHeading | pubmed-meshheading:18762671... | lld:pubmed |
| pubmed-article:18762671 | pubmed:year | 2008 | lld:pubmed |
| pubmed-article:18762671 | pubmed:articleTitle | Abciximab in coronary intervention for acute myocardial infarction and stable ischemic heart disease: early investment for growing benefit. | lld:pubmed |
| pubmed-article:18762671 | pubmed:affiliation | International Centre for Circulatory Health, National Heart and Lung Institute, Imperial College and St. Mary's Hospital, 59-61 North Wharf Road, London W2 1LA, United Kingdom. emily.ferenczi@doctors.org.uk | lld:pubmed |
| pubmed-article:18762671 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:18762671 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
